Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Page 86:
---------------------------------
VASCEPA ORAL CAPSULE 0.5 GRAM, 1 GRAM 2
You can Sleep without worries. You seem to assume the RS were 10 - actually it were 20 - so the truth is' - the SP has hardly moved (equivalent of SP $ 0.55 today).
-------------------------------
Will it change for the better going forward ?
I still hold +3.000 shares (used to be 60.000 shares) before the recent RS.
As long as the stock is not 'dead all together' - the chance of Improvement / BO is always there' - but living with AMRN for seven years - trust in 'a happy ending' is running thin - have to admit 😒
What I blame myself the most - loosing value of 5- 6 Tesla 3's - on this haunted stock:
--------------------------------
SP of AMRN were at $6.63 on day that KM took over as CEO - (equivalent of + $132 today).
I actually believed this guy being "an expert on Europe" - would be able to get the company moving' - and did expand investing extensively ! How Stupid / Wrong was I 🥴
Chromosome, Lost our shirt - trousers and shoes - all because of a totally FU justice system in the US.
---------------------------------------------------------------------
A random judge - in one of 50 states - Can - IN ONE SINGLE RULING BASED ON FRAUD - totally smash / ignore 10 years of scientific work at the USPTO gaining the crucial 6 patents, built on Amarin using more than 100 mill. dollars on the - 'Reduce It' - trial,
------------------------------------------------
USA has a SICK justice system - explaining why there there is more than double the numbers of layers 'pr. number of citizen's - than any where else in the World 👇️
-------------------------------------------------
Truth is - the product thousand of serious investors bought into - were / is one of the greatest products EVER - protecting your health - but US SICK justice system made a fool out of anyone that ever invested seriously into the hard bought science behind the Stock.
Bearish - Know why you said that' - but where we are (rock bottom) - there is not much more left to loose - right'.
-------------------------------
From your inputs here I take it you have held on to your AMRN stocks /ever suffering) like most of the rest of us here.
Remember your dream were a Beach House - will AMRN ever get you that - maybe not - but as long as you 'haven't sold' - the possibility of a serious 'turn around' - BO is still there ✌️
All the best !
Jasbg
OK - got a little carried away - over Whala's endless calling for more trials.
My apologiens to him and North - and a good weekend to everyone 🙂
Jasbg
Whala, DOES IT - again - again - again - again - again - again - as he has done thousands of times before on this board.
---------------------------------------------
This time taking one of most trusted posters - 'North' - on a ride' - doing everything' - to keep influence / control of this board.
---------------------------------------------
As I have asked many times before' - what is the goal of this guy doing +22.000 posts here - not owning any AMRN shares - mostly recommending other Bio shares in his endless posts !
Thanks North ! 22.000 posts - no AMRN shares - have you any idea his motives for EVER and AGAIN - in thousands of posts - trying to undermine trust in powerful science behind Vascepa ?
RMB, Have to disagree with you for onse.
Everyone here 'has run into Whala / Kiwi' again and again !
Do you 'know who he is' '- where he lives - his reasons for EVER demanding more trials on Vascepa ?
He have repeatedly said he ovnes 'no AMRN' shares' - and usually (very often) recommend other Bio Shares instead !
Interesting for US Citizens;
https://truthsocial.com/@realDonaldTrump/posts/114491534347862682
Whala - + 22.000 posts - no AMRN shares - thousands of posts on 'MORE TRIALS' !
----------------------------------
One can't help wonder - What is driving this guy - using years on this failed Stock - ever trying to undermine (building mistrust) in the fantastic 'proven data' Vascepa is build on - why generics are falling over each other - to get on the EPA train !
-----------------------------------
Who is this Guy - WHALA - who has spend more than 6 years undermining R-I results - does anyone here actually know ?
Short story is' - that AMRN has been a disaster in investing for 98% of people still here om Ihub board.
For me personally - I used to measure loss in number of Tesla 3's (used to bee 6 +) - now Musk deeds - helped me down to around 5 (not that I will ever buy one - I'm diesel till I die) 😀
Here a little something about AMRN:
Visible to me 😀
ORBAPU, You forget to mention that Nissens STRENGHT trial were based on EPA+DHA - basically the Fish Oil you can buy OTC everywhere.
VASCEPA - used in REDUCE-IT tral - is 8 times purified EPA - encapsulated in patented advanced process,
Comparing the two trials is absolute nonsense.
------------------------------------
https://pubmed.ncbi.nlm.nih.gov/33993205/
------------------------------------
But as most of here will recall' - Steve Nissen - simply couldn't accept that his STRNGHT trial were a total failure that were stopped early.
https://www.tctmd.com/news/fish-oil-tanks-strength-making-waves-reduce-it
Stocks - takes months / years to grow' - days / hours to fall' !
---------------------------------------------------------
My wife always' when the market is rotten (like it has bin for the latest months) - why did 'nt you just sell 'on the top' ?
And I defend myself - 'the top' is very difficult to predict - as in IMPOSSIBLE - (and never there for long) - talking Stocks and the Market 🙂
north, I said years ago - if you had an ETF on your Portfolio' - I would put all my money in that Index of yours 🙂
I' - 100% opposite WHLA - expect the US Market to 'explode' within the next months !
-----------------------------------------------
With the 'historich' 47 new administration disruption WW'- a US market Astronomical Comeback has to happen 😀
-----------------------------------------------
Where this will leave AMRN is a different matter' - this 'until now' haunted Stock - can go Either Way - 'gain momentum - and finally reward longtime investors' - or fall through the generic 'mined' roof' - with no way back 😀
ORBAPU, Anyone know if the - 'JL' your talking about - 'is still around and breeding' ?
------------------------
Remember how this guy bragged (in other forums) about having made more than $1,5 mill. dollars on AMRN - out at around $18 using options' - to protect himself before the disastrous Nevada Court Ruling ?
Wish I had his brains 🙂
Here a little Easter reading on the impact of DeepSeek - earlier this spring.
It took one of my (until then) best investments MRVL from above $120 - till now around $50 🥲
https://medium.com/the-simulacrum/deepseek-r1-broke-the-camels-back-031840e4da22
DMC8, Thanks for your ever continued searching 'real information / news' informing the rest of us - about Vascepa / Vazkepa.
----------------------------------------
What is you take on the - BIG news out of China ?
Can vi hope the news is something that will take SP in the right direction in the short run ? :🙂
biopa, Democracy ! You mean the totally RIGGED 2020 - (Sorrows - Bloomberg paid for) - inspirational 2020 Election ?
-------------------------------------------------------
The closest US have been a real 'DEMOCRACY' - for a long time - is 2024 Election ✌️
🙂 !!!
Rahrah; - Alias Born: 07/07/2002 01:14:40 PM - your are old as Methuselah 🙂
------------------------------------------------------------------
Criticizing 45 - on economy politics - is just so much 'not understanding anything' of what this Multi Billionaire Patriot is doing for his Country.
First 45 term - he had to fight the deeply corrupt Left and Media - his whole 4 years. !
-------------------------------------------------------------------
This time 47 different - which the rest of this world have already noticed.
If I were US Citizen I would be very exited to follow development in the 47 period - economically - and otherwise - looking into a Better Future 🙂
MMS, Everyone is 'down' (me MRVL - MAGS) 50% since before Christmas.
Pensions fonds - general down 30- 40% - in EU - everyone is down BIG this spring !
-------------------------------------------------
Personally - being a big 47 believer - I trust that the tide will turn' - before not to long in the US market 'general' - and from where we are - there is still a good chance of AMRN gaining momentum at some point. China - hanging EU countries ROW.
Now 20 mill shares - doesn't take much' to make this PROVEN Bio company interesting for BP as a BO 🙂
ramfan60, I hope this interview will be aloud to stay - as it perfectly explains what the 47 plan is all about 🙂
https://www.foxnews.com/video/6370975230112
Thanks Lizzy - I will sure sleep better now 🙂
---------------------------------
Exiting times ! How will Friday and the coming weeks turn our for AMRN ? 🙂
A dumb question.
What happens if the amount of your shares doesn't' divide into 20 - do you then own EG 2900,1288 shares ? 🙂
--------------------------------------------------
Interesting markets these days - almost like the weather reports - new records every week - after John Coleman no longer with us 🙂
Canes: WRONG !!!
---------------------------
USA is in the most exiting times after WW2 !
Cleaning Out EU socialist influence - FINALLY working at - 'Making Level Playing field' - against Asian Competition
----------------------------
In the end everything is about - the terms of Exchange in Currencies - where Asia and EU - to put it nicely - 'for 40 years 'Have Scr*wed USA'
RMB - It is leading absolutely nowhere going after / blaming Denner and the Board for the state of Amarin today.
---------------------------
Two things:
1. Only reason Sarissa is here - is a random judge' in a random state' - in a single ruling based on fraud - totally smashed 10 years work by experts at the USPTO granting the 6 patents.
2. The cash would be long gone - if it weren't for the entrance of Denner and the current board.
BBI, With you all the way here'. Where we are (in value) - we just have to trust/believe that Sarissa/Denner have a plan.
This is 'What They Do' - how Denner made his Business - Making turnarounds in the Market' - against experts expectations'.
------------------------------------------------
Truth is that Amarin and Vascepa/Vazkepa is even further out than Trump' - aiming to concur this Planet - so no reason to Give up Hope - Yet 🙂
In all our misery - it is important to remember - that Sarissa is only invested here because of the ruling by Nevada Judge Du (based on fraud) that smashed the protecting patents that Amarin spend more than 100 mill dollars to gain.
Sarissa and Denner's game- is investing in what they see as undervalued Stocks - and when Du opened the gates for Generics - SP collapsed - they saw Amarin as being undervalued.
Without the Nevada 'for investors' catastrophic ruling - no one here' would have ever heard of Denner in relation to Amarin and Vascepa.
Not news to anyone here' - but fine R-I mentioned 'again' 🙂
10.2.2. Icosapent Ethyl
Icosapent ethyl [eicosapentaenoic acid (EPA)] is approved in international guidelines for high-risk patients with hypertriglyceridemia on statins [231]. The REDUCE-IT trial reported a 25% reduction in cardiovascular events with EPA use [232]. EPA exerts several protective mechanisms, including stabilizing cell membranes, inhibiting lipid oxidation and downregulating proinflammatory pathways such as NF-?B [233]. In addition, EPA limits the differentiation of T cells into the proinflammatory Th1 subtype [234], while promoting atheroprotective Treg cell differentiation [235]. Furthermore, EPA has been associated with reduced cytokine IL-6 [236]. EPA can also be metabolized into the lipid mediator resolvin E1, which reduces oxLDL uptake by macrophages and binds to the specific resolvin receptor ChemR23, expressed on ECs, to mediate inflammation [237].
This Townsendletter holds an enormous amount of information - pointing here and there on both EPA and DHA. The conclusion is weak and unclear to mee.
----------------------------------------
Only information that is reasonable clear in all the data - we have all seen before;
Although both EPA and DHA decreased triglyceride level and increased HDL-C in earlier studies, those studies also showed that DHA “has more undesirable effects on LDL.” EPA does not have the same effect on LDL. “Furthermore, the MARINE and ANCHOR trials have both shown that not only does EPA improve the lipid panel but also helps to decrease the levels of the vascular inflammatory biomarkers, thus further helping to decrease cardiovascular risk.”14
As AMRN investors - we can hope the miracle molecule of Vascepa - will be at some point be recognized - and the 'steal from Generics - made possible by a local state liberal judge - be reversed with full compensation 🙂✌️
---------------------------------------
Under here an interesting input - from someone with the background to have a qualified opinion of where this is all leading 🙂
Surely on the Top5 list of all-time best movie's ever 🙂
Cant help to put JT here once again - to convince myself - that what happened', now more than 5 years back, is actually for real !
Look at the wall with SP behind JT - and weep 🙂
Is this NEWS' - for US Tax payers ?
'Follow The Money' ✌️
-------------------------------
https://rumble.com/v6hmruj-they-fell-right-into-trumps-trap-ep.-2417-02062025.html
https://rumble.com/v6i1ffg-doge-uncovers-more-corruption-than-we-ever-thought-possible-ep.-2418-020720.html
-------------------------------
Could this all being exposed' - lead to a better 'More Honest' World in the future ? My hope is that it actually Will' 🙂
It's not only TikTok - the Chinese are at again' - only worse this time 👎️
Same question and answer DeepSeek:
---------------------------------------------------
Where will SP of AMRN be end 2025 ?
Alright, the user is asking where the stock price (SP) of Amarin Corporation (AMRN) will be at the end of 2025. Let me break this down. First, I need to recall what Amarin does. They're a pharmaceutical company, right? Their main product is Vascepa, which is used for cardiovascular risk reduction. But I remember there was some patent litigation a few years back, which might have affected their stock.
So, predicting a stock price years ahead is tricky. Stocks are influenced by so many factors: company performance, market trends, regulatory changes, competition, etc. For a pharma company like Amarin, drug approvals, patent expirations, and clinical trial results are especially important. Let me think about their current situation. Vascepa was their flagship drug, but after losing patent protection, generics might have entered the market, which would reduce revenue. Have they been developing new drugs or expanding into new markets? That could be a positive sign.
I should check their recent financials. If their revenue is declining due to generic competition and they're not diversifying their pipeline, the stock might struggle. On the other hand, if they have promising drugs in the pipeline or strategic partnerships, that could boost investor sentiment. Also, the overall market conditions in 2025 matter. If the economy is in a downturn, even good news might not lift the stock much.
Another angle is technical analysis. Looking at historical stock performance, support/resistance levels, but that's more short-term. For a long-term prediction like 2025, fundamentals are more relevant. Also, considering the company's cash reserves: if they're burning through cash without a clear path to profitability, that's a red flag. Conversely, if they manage to cut costs or secure new funding, that could help.
I should also consider analyst ratings and price targets. Have analysts revised their outlooks for AMRN recently? What's the consensus? But analysts can be wrong, so it's just one data point. Additionally, any news about mergers or acquisitions? If Amarin is a takeover target, that could spike the stock price.
Regulatory factors are key too. Any pending FDA approvals or rejections? Clinical trial results expected before 2025? Positive results could lead to surges, while failures could cause drops. Also, healthcare policy changes, like drug pricing reforms, could impact their revenue.
Competitor activity is another factor. If other companies have better or cheaper alternatives, that could hurt Amarin's market share. Conversely, if they have a unique product with strong demand, that's a plus.
Looking at their management team. Have there been recent changes in leadership? A strong management team can navigate challenges better. Also, any insider trading activity? If executives are buying shares, that might indicate confidence.
Macro factors like interest rates. If rates are high in 2025, growth stocks (like biotech) might be less attractive compared to bonds. But if rates are low, investors might seek higher returns in stocks.
Putting it all together, Amarin's future stock price hinges on their ability to innovate beyond Vascepa, manage generic competition, secure regulatory approvals, and maintain financial health. Without significant positive developments, the stock might remain under pressure. But if they have successful new drugs or partnerships, it could rise. Given the uncertainty, it's a speculative bet. Analysts might have varied opinions, but without concrete data, it's hard to pinpoint. The user should consider consulting financial advisors and doing their own research, maybe looking into the company's pipeline and financial statements for better insight.
Predicting the exact stock price of Amarin Corporation (AMRN) at the end of 2025 involves significant uncertainty due to variables such as market dynamics, company performance, regulatory changes, and macroeconomic conditions. However, here’s a structured analysis of factors that could influence AMRN’s trajectory:
Key Considerations:
Product Pipeline & Revenue Drivers:
Vascepa: AMRN’s primary revenue source faced generic competition after patent losses in 2020–2021. Future performance depends on market retention, international expansion (e.g., Europe), or potential label expansions.
Pipeline Development: Progress in new drug candidates (e.g., cardiovascular therapies) or acquisitions could revive growth. Lack of pipeline diversification poses risks.
Financial Health:
Cash reserves and cost management are critical. As of 2023, AMRN has focused on reducing expenses; sustainability of this strategy will impact its ability to fund R&D or partnerships.
Regulatory and Clinical Catalysts:
FDA/EMA approvals for new indications or drugs, trial results, or partnerships (e.g., with pharma distributors) could drive upside. Setbacks may pressure the stock.
Market Sentiment:
Biotech stocks are sensitive to investor risk appetite. Macro factors like interest rates and sector trends (e.g., demand for cardiovascular drugs) will play a role.
Competition:
Growth of generic alternatives and rival therapies (e.g., other triglyceride-lowering drugs) may limit Vascepa’s market share.
Scenarios for 2025:
Bull Case (
10
–
10–20+):
Successful pipeline advancements, international expansion of Vascepa, or strategic partnerships/acquisitions. Positive clinical data or a buyout could spur momentum.
Base Case (
5
–
5–10):
Stabilized revenue from existing markets, cost controls, and modest pipeline progress. Stock may trade sideways without major catalysts.
Bear Case (<$5 or delisting):
Continued revenue decline, pipeline failures, or liquidity challenges. Generic competition erodes margins, leading to further downside.
Analyst Sentiment:
As of 2023, AMRN has mixed ratings, with some analysts cautious due to reliance on Vascepa and uncertain growth drivers. Long-term optimism hinges on execution of turnaround strategies.
Conclusion:
AMRN’s 2025 stock price is highly speculative. Investors should monitor:
Quarterly earnings and cash burn.
Pipeline updates (e.g., Phase 3 trials).
Partnerships or M&A activity.
Regulatory decisions in international markets.
Final Note: This analysis is not financial advice. Consider consulting a financial advisor and reviewing AMRN’s SEC filings, earnings calls, and industry trends for informed decisions.